This 2020 narrative review examines the role of thyroid hormones and prolactin in modulating cognitive function in patients with major mood disorders and schizophrenia. It highlights that cognitive impairment is a core symptom of these disorders and remains inadequately addressed by current treatments. Subclinical hypothyroidism and low free thyroxine (FT4)
